Global pharma major Lupin Limited has announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, to market a generic equivalent of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, of Janssen Research and Development, LLC.

Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US (IQVIA MAT August 2022).

Lupin, an innovation-led transnational pharmaceutical company, develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas.

Lupin is the third-largest pharmaceutical company in the US by prescription. The company invested 8.7% of its revenue in research and development in FY22. The company has 15 manufacturing sites, 7 research centers, and more than 20,000 professionals working globally.